Budemide-F Respules
Formoterol 20 mcg + Budesonide Respules — Combination ICS + LABA Nebulizer Therapy
| Composition | Formoterol 20 mcg + Budesonide per 2 ml respule |
|---|---|
| Dosage Form | Nebulizer Respule |
| Pack Type | Respule Pack |
| Pack Size | 5 x 4 Respules (20) |
| MRP | ₹ 1200 |
| Therapy | G.P. + Gynaecology / Respiratory — Inhaled Corticosteroid + Long-Acting Beta-2 Agonist (ICS+LABA) |
| Storage | Store below 25 °C, protected from light. Use immediately after opening foil sachet. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Budemide-F Respules
Budemide-F Respules combine the long-acting beta-2 agonist Formoterol 20 mcg with the inhaled corticosteroid Budesonide in a single 2 ml nebuliser respule. It is used for the maintenance therapy of moderate-to-severe persistent asthma and COPD in adults — where combined ICS + LABA therapy provides better symptom control than either component alone.
Formoterol is a fast-onset (within 1–3 minutes) and long-duration (12-hour) beta-2 agonist that produces sustained bronchodilation. Budesonide simultaneously suppresses airway inflammation that drives bronchial hyperreactivity. The combination is supported by GINA guidelines as step-up therapy from ICS monotherapy in moderate asthma.
Budemide-F is manufactured by Trumac Healthcare under WHO-GMP conditions. Available for monopoly-based PCD pharma franchise and third-party manufacturing — a high-value respiratory SKU.
Indications
- Maintenance therapy of moderate-to-severe persistent asthma
- COPD with frequent exacerbations
- Asthma inadequately controlled on ICS monotherapy
- Step-up therapy when short-acting bronchodilator use is frequent
Mechanism of Action
Formoterol selectively activates β2-adrenergic receptors on airway smooth muscle, raising cAMP and producing sustained bronchodilation lasting 12 hours. Budesonide binds glucocorticoid receptors in airway tissue, suppressing pro-inflammatory gene transcription and reducing airway hyperreactivity. The combination targets both bronchospasm and underlying inflammation.
Dosage & Administration
Adults: 1 respule by nebulisation twice daily. Rinse mouth after each use to prevent oral candidiasis. To be prescribed by a physician.
Side Effects
Tremor, palpitations, headache (Formoterol). Oral candidiasis, dysphonia, throat irritation (Budesonide). Rare: paradoxical bronchospasm, hypokalaemia with high doses.
Contraindications & Precautions
Hypersensitivity to either component. Tachyarrhythmias. Severe cardiovascular disease (caution). Untreated bacterial respiratory infection. Children < 12 years for this strength.
Storage
Store below 25 °C, protected from light. Use immediately after opening foil sachet.
Budemide-F Respules is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Budemide-F Respules used for?
Budemide-F Respules combine Formoterol and Budesonide for maintenance therapy of moderate-to-severe asthma and COPD requiring combined ICS + LABA therapy.
How does Budemide-F differ from Budemide-0.5?
Budemide-0.5 is Budesonide alone (anti-inflammatory). Budemide-F adds Formoterol, a long-acting bronchodilator — used when asthma is inadequately controlled on ICS alone.
Is Budemide-F available for PCD pharma franchise?
Yes, Trumac Healthcare offers Budemide-F on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Budemide-F be stored?
Store below 25 °C, protected from light. Use immediately after opening foil sachet.
Is Budemide-F WHO-GMP certified?
Yes, manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Budemide-0.5 Respules (4 x 5 Pack) — Budesonide 0.5 mg / 2 ml per respule
- Budemide-F1 Respules — Formoterol 20 mcg + Budesonide 1 mg per 2 ml respule
- Budemide-Forte Respules — Budesonide IP 1 mg / 2 ml per respule